Research
Hormonal
Fructose consumption promotes disease progression from simple steatosis to nonalcoholic steatohepatitis (NASH) by inducing oxidative stress, endoplasmic reticulum (ER) stress, and inflammation via mechanisms including uric acid production and methylglyoxal accumulation.
If you have fatty liver, reducing fructose is crucial not just for fat loss but to stop the inflammation and stress that turn simple fat accumulation into serious liver disease (NASH).
GoodSupportsHIGH confidence
Beyond its lipogenic effect, fructose intake is also at the onset of hepatic inflammation and cellular stress, such as oxidative and endoplasmic stress, that are key factors contributing to the progression of simple steatosis to nonalcoholic steatohepatitis (NASH).
Why this rating
Supported by multiple mechanistic studies in humans and rodents cited in the review.
Source
Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism
Prasanthi Jegatheesan et al. · Nutrients · 2017
DOI 10.3390/nu9030230
narrative_reviewCited 274×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Excessive fructose consumption promotes nonalcoholic fatty liver disease (NAFLD) by acting as both a substrate and an inducer of hepatic de novo lipogenesis (DNL), leading to lipid accumulation and subsequent oxidative stress and inflammation.Good
- Fructose consumption negatively impacts peripheral tissues (gut, muscle, adipose) through interorgan cross-talk, leading to gut dysbiosis, visceral adiposity, and muscle insulin resistance/sarcopenia.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →